Skip to main content

Table 1 Clinical performance of CLART4S and MGP-PCR in SurePath and ThinPrep cervical cancer screening samples

From: Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening

Specificity and Sensitivity (95% Confidence Interval)

 

SurePath

ThinPrep

Accuracy parameter

CLART4S

MGP-PCR

CLART4S

MGP-PCR

Specificity <CIN2

1074/1184

(0.91; 0.89–0.92)

1078/1184

(0.91; 0.89–0.93)

1096/1169

(0.94; 0.92–0.95)

1013/1169

(0.87; 0.85–0.89)

Relative Specificity

1.0

(0.97–1.02)

1.0

1.1

(1.05–1.11)

1.0

Sensitivity ≥CIN2

73/81

(0.90; 0.81–0.96)

75/81

(0.93; 0.85–0.97)

78/80

(0.98; 0.91–1.00)

80/80

(1.00; 0.95–1.00)

Relative sensitivity

0.97

(0.89–1.07)

1.0

0.98

(0.94–1.01)

1.0